Overview
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
Eligibility
Inclusion criteria:
- Patients who have started at first time on Jardiance® in accordance with the approved label in Korea for heart failure (HF)
- Chronic heart failure (New York Heart Association (NYHA) class II-IV)
- Age ≥ 19 years at enrolment
- Patients who have signed on the data release consent form
Exclusion criteria:
- Patients with previous exposure to Jardiance®
- Known allergy or hypersensitivity to active ingredients empagliflozin or to any of the excipients
- Patients with type 1 diabetes or with prior history of diabetic ketoacidosis (DKA)
- Patient with renal impairment with estimated Glomerular Filtration Rate (eGFR) < 20 mL/min/1.73 m²
- Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- Patient who are pregnant or are nursing or who plan to become pregnant while in the trial
- Patients for whom empagliflozin is contraindicated according local label of Jardiance®